Et al Phillip Frost MD - 24 Feb 2026 Form 4 Insider Report for Cocrystal Pharma, Inc. (COCP)

Role
Director, 10%+ Owner
Signature
/s/ Phillip Frost, MD ET AL
Issuer symbol
COCP
Transactions as of
24 Feb 2026
Net transactions value
+$19,952
Form type
4
Filing time
25 Feb 2026, 16:10:11 UTC
Previous filing
09 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
FROST PHILLIP MD ET AL Director, 10%+ Owner 4400 BISCAYNE BLVD, MIAMI /s/ Phillip Frost, MD ET AL 25 Feb 2026 0000898860

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction COCP Common Stock Purchase $19,952 +20,000 +1.1% $0.9976 1,908,551 24 Feb 2026 By Frost Gamma Investments Trust F1, F2
holding COCP Common Stock 27,100 24 Feb 2026 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions ranging from $0.98 to $1.00, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares purchased at each separate price within the ranges set forth in the preceding sentence.
F2 These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3 Includes shares of common stock issuable upon vesting of restricted stock units.

Remarks:

This Form 4 does not include any of the securities owned directly by OPKO Health, Inc., a company of which Dr. Frost is the Chairman of the Board and Chief Executive Officer, concerning the securities of which Dr. Frost does not hold voting and investment control. Dr. Frost disclaims beneficial ownership of the securities held by OPKO Health, Inc. except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.